The Dexcom G7 lawsuit problems in 2026 center on sensor failures, inaccurate glucose readings, and adhesive defects that allegedly put diabetic patients at serious risk. Thousands of users have reported that their G7 device gave dangerously wrong blood sugar numbers, leading to insulin dosing mistakes, emergency room visits, and worse.
If you wore a Dexcom G7 sensor and experienced any of these malfunctions, you may be eligible to join the growing wave of legal claims. The FDA has received thousands of adverse event reports tied to this device.
This article breaks down every angle of the Dexcom G7 lawsuit for 2026. You will find estimated payout ranges, eligibility rules, filing steps, the latest case updates, tax questions, and settlement funding options. One fact that stands out: some individual injury claims in similar medical device cases have produced settlements worth $50,000 to $250,000 or more per plaintiff.
Dexcom G7 Lawsuit Problems
Dexcom G7 lawsuit problems refer to the legal claims filed against Dexcom Inc alleging that its G7 continuous glucose monitor contains design and manufacturing defects. These defects reportedly cause the device to give incorrect blood sugar readings, fail to alert users to dangerous glucose levels, and detach from the skin prematurely.
The core allegation is straightforward. The G7 was supposed to help diabetic patients manage their blood sugar safely. Instead, plaintiffs say it created new dangers.
Problems cited in lawsuits and FDA reports include:
- Sensor failures during the 10-day wear period
- False low readings that led users to consume unnecessary sugar
- False high readings that caused patients to take excess insulin
- Complete signal loss between the sensor and the smartphone app
- Adhesive failures causing the sensor to fall off prematurely
- Warm-up errors where the sensor never calibrated properly
These aren’t minor inconveniences. For a person with Type 1 diabetes, a wrong reading can trigger a medical emergency within minutes. Taking insulin based on a falsely high reading can cause severe hypoglycemia, seizures, or loss of consciousness.
| Problem Type | Reported Impact |
|---|---|
| False low glucose reading | Unnecessary carb intake, weight issues |
| False high glucose reading | Insulin overdose, hypoglycemia, ER visits |
| Total sensor failure | Unmonitored glucose for hours |
| Adhesive detachment | Lost data, unprotected monitoring gaps |
| App connectivity loss | Delayed or missing glucose alerts |
Dexcom Inc, based in San Diego, California, has publicly defended its G7 product. But the volume of complaints tells a different story.
Dexcom G7 Lawsuit Update 2026
As of early 2026, Dexcom G7 lawsuits are in the active investigation and filing phase across multiple federal jurisdictions. No formal class action settlement has been reached yet, but the number of individual injury claims continues to grow.
Several plaintiff law firms began aggressively filing cases in late 2024 and throughout 2025. By early 2026, the litigation has reached a point where legal observers expect possible consolidation into multidistrict litigation, also known as an MDL.
An MDL would pool many individual cases before a single federal judge. That judge would handle pretrial proceedings like discovery and expert testimony. This is how most large medical device lawsuits move forward.
Key developments to watch in 2026:
- MDL petition status: A formal request to the Judicial Panel on Multidistrict Litigation could come at any time
- Discovery phase: Plaintiffs’ attorneys are seeking internal Dexcom documents about known defects
- Bellwether trials: If an MDL forms, the court will select a few representative cases to try first
- FDA enforcement actions: Any new recalls or warning letters from the FDA could strengthen plaintiffs’ claims
| 2026 Milestone | Expected Timing |
|---|---|
| MDL consolidation decision | Mid 2026 |
| Document discovery begins | Q2 to Q3 2026 |
| First bellwether trial selections | Late 2026 to early 2027 |
| Potential settlement discussions | 2027 or later |
The litigation is still early. But momentum is building.
Dexcom G7 Class Action Lawsuit 2026
The Dexcom G7 class action lawsuit in 2026 is not yet a certified class action in the traditional sense. Most current claims are individual product liability lawsuits, though some attorneys are pursuing class action certification for economic damages.
Here is the difference. A class action groups all affected people into one case with one outcome. Individual lawsuits let each plaintiff argue their unique injuries and damages separately.
For the Dexcom G7, the legal strategy appears to be splitting into two tracks:
- Individual injury lawsuits for people who suffered physical harm (hypoglycemia, hospitalization, diabetic ketoacidosis)
- Class action claims for economic losses (cost of the device, replacement sensors, out-of-pocket medical expenses)
Think of it like a tree with two main branches. Both grow from the same root problem, but they lead to different types of compensation.
If a class action is certified in 2026, it would likely cover users who purchased the G7 and experienced documented malfunctions, even if those malfunctions did not cause physical injury. The goal would be refunds or reimbursement.
Individual injury cases, on the other hand, aim for much larger payouts. These cover medical bills, pain and suffering, lost wages, and emotional distress.
| Lawsuit Type | Goal | Potential Payout Range |
|---|---|---|
| Class action (economic) | Refund, reimbursement | $100 to $1,500 per claimant |
| Individual injury claim | Full compensation | $50,000 to $250,000+ |
| Wrongful death claim | Survivor compensation | $500,000 to $1,000,000+ |
Both paths remain open for affected Dexcom G7 users in 2026.
Key Takeaway: The Dexcom G7 litigation is active and growing in 2026, with multiple lawsuit types available depending on whether you suffered financial losses, physical injuries, or both.
Dexcom G7 Lawsuit Payout
Dexcom G7 lawsuit payout amounts have not been finalized because no settlement has been approved yet. However, based on similar medical device lawsuits, legal analysts project a wide range depending on the severity of harm.
Medical device product liability cases in the United States follow a pattern. Payouts scale with the seriousness of the injury and the strength of the evidence connecting the device to the harm.
Here is what comparable cases suggest:
- Minor harm (brief sensor failure, no ER visit): $5,000 to $25,000
- Moderate harm (incorrect reading led to ER visit or overnight observation): $25,000 to $100,000
- Serious harm (hospitalization, diabetic ketoacidosis, prolonged medical treatment): $100,000 to $250,000
- Catastrophic harm (permanent injury, brain damage from severe hypoglycemia): $250,000 to $500,000+
- Wrongful death (death linked to device failure): $500,000 to over $1,000,000
These are projections, not guarantees. Each case depends on medical records, device logs, and the plaintiff’s specific situation.
| Injury Severity | Estimated Payout Range |
|---|---|
| Minor (no ER visit) | $5,000 to $25,000 |
| Moderate (ER visit) | $25,000 to $100,000 |
| Serious (hospitalization) | $100,000 to $250,000 |
| Catastrophic (permanent injury) | $250,000 to $500,000+ |
| Wrongful death | $500,000 to $1,000,000+ |
If you kept the faulty sensor, saved Dexcom app screenshots, or have medical records showing a device-related incident, your claim will be much stronger. Documentation is everything in these cases.
Dexcom G7 Settlement Amount
The Dexcom G7 settlement amount will ultimately depend on the total number of claimants, the severity of injuries across all cases, and whether Dexcom chooses to settle or fight in court. No global settlement figure has been announced as of 2026.
In comparable medical device mass torts, total settlement funds have ranged from $100 million to several billion dollars. The Medtronic Infuse bone graft settlement, for example, totaled over $2.6 billion. The DePuy hip implant settlement exceeded $2.5 billion.
The Dexcom G7 case is different from those examples in one important way. Most reported injuries are acute episodes (ER visits, insulin reactions) rather than permanent implant failures. This typically means lower per-plaintiff payouts but could still result in a massive overall settlement pool due to the sheer number of affected users.
Dexcom sold millions of G7 sensors since the device launched in 2023. Even if a small percentage of users experienced problems, the total claim count could be enormous.
Factors that will determine the final settlement amount:
- Total number of filed claims
- Strength of internal evidence showing Dexcom knew about defects
- Outcomes of any bellwether trials
- Whether the FDA takes additional enforcement action
- Public pressure and media attention
Quick Fact: Dexcom Inc reported over $3.6 billion in revenue for 2024. The company has the financial capacity to fund a significant settlement.
Dexcom G7 Lawsuit Eligibility
Dexcom G7 lawsuit eligibility depends on whether you used the device during the relevant period and experienced a documented malfunction or injury. You do not need to have been hospitalized to qualify, though more serious injuries strengthen a claim.
General eligibility criteria that attorneys are using in 2026:
- You used a Dexcom G7 sensor at any point since its market launch in 2023
- Your sensor gave inaccurate glucose readings (high or low)
- Your sensor failed completely during the wear period
- Your sensor detached due to adhesive failure
- You experienced a health consequence connected to the device malfunction
- You have medical records, app data, or other documentation of the problem
| Eligibility Factor | Required? |
|---|---|
| Used Dexcom G7 sensor | Yes |
| Experienced device malfunction | Yes |
| Have medical records or documentation | Strongly recommended |
| Suffered physical injury | Not required, but increases payout |
| Filed an FDA complaint | Not required, but helpful |
| Have the defective sensor | Not required, but helpful |
You don’t need to have filed a complaint with the FDA or Dexcom to be eligible. You don’t need to have kept the faulty sensor either. But both of those things help.
If you used a Dexcom G6 rather than the G7, separate legal claims may apply. The current wave of litigation focuses primarily on the G7 model.
Key Takeaway: You qualify for the Dexcom G7 lawsuit if you used the device since 2023, experienced a malfunction, and can provide any form of documentation connecting the device to your problem.
Who Qualifies for Dexcom G7 Lawsuit
Anyone who wore a Dexcom G7 continuous glucose monitor and experienced a sensor malfunction, inaccurate reading, or injury linked to the device may qualify for this lawsuit. This includes both Type 1 and Type 2 diabetes patients.
The qualification bar is broader than most people think. You don’t have to prove you nearly died. A pattern of unreliable readings that forced you to buy fingerstick test strips as a backup could count as an economic claim. A single severe hypoglycemic episode caused by a false reading could support an individual injury claim.
People who may qualify include:
- Diabetic patients who relied on the G7 for daily glucose monitoring
- Parents of children with diabetes who used the G7 on their child
- Caregivers who managed a patient’s diabetes using G7 data
- People who were hospitalized after a G7 malfunction caused an insulin error
- People who suffered DKA (diabetic ketoacidosis) when the G7 failed to alert to high blood sugar
Even if you switched to a different CGM device after your G7 problems, you can still file a claim for the period when you used the G7.
One group that is sometimes overlooked: people who experienced emotional distress from losing trust in their glucose monitor. Living with diabetes is already stressful. Discovering that your monitoring device can’t be trusted adds a layer of anxiety that some courts recognize as compensable.
Dexcom G7 Sensor Failure Lawsuit
The Dexcom G7 sensor failure lawsuit targets cases where the G7 sensor stopped working entirely during its intended 10-day wear period. Complete sensor failure means the user had zero glucose monitoring for hours or even days.
For someone with insulin-dependent diabetes, that’s like driving at night with your headlights off. You’re moving forward, but you can’t see what’s coming.
Reported sensor failures include:
- Sensor dies within the first 24 hours of application
- Sensor displays “sensor error” and never recovers
- Sensor stops transmitting data to the phone app mid-cycle
- Sensor gives a “replace sensor” alert days before the 10-day period ends
Each of these failures forces the user to either apply a new sensor (at additional cost) or rely on painful fingerstick blood tests. Dexcom sensors are not cheap. A single sensor costs approximately $75 to $100 without insurance.
| Failure Scenario | Risk Level |
|---|---|
| Sensor dies in first 24 hours | High (no baseline established) |
| Mid-cycle signal loss | Very High (gap in monitoring) |
| Early termination warning | Moderate (some data still available) |
| Intermittent connection drops | High (unreliable data) |
Plaintiffs in sensor failure cases argue that Dexcom knew about high failure rates from internal quality control data but continued selling the product without adequate warnings.
Key Takeaway: Sensor failures, inaccurate readings, and adhesive problems are the three main categories of Dexcom G7 defects driving lawsuits, and all three can cause serious medical consequences for diabetic patients.
Dexcom G7 Inaccurate Readings Lawsuit
The Dexcom G7 inaccurate readings lawsuit focuses on cases where the device displayed blood sugar numbers that were significantly different from actual glucose levels. This is arguably the most dangerous defect because users act on the information the device gives them.
Here is why inaccurate readings are so harmful. If the G7 shows a blood sugar of 250 mg/dL when your actual level is 120 mg/dL, you might take a large dose of insulin. That extra insulin could crash your blood sugar below 50 mg/dL, causing confusion, seizures, or unconsciousness.
The opposite scenario is equally dangerous. If the G7 shows 90 mg/dL when your real level is 300 mg/dL, you won’t take the insulin you need. Your blood sugar keeps climbing, potentially leading to diabetic ketoacidosis, a life-threatening condition.
Reported accuracy problems include:
- Readings off by 50 mg/dL or more compared to fingerstick tests
- Consistently low readings that masked dangerously high glucose
- Consistently high readings that prompted unnecessary insulin doses
- Rapid reading fluctuations that did not match the user’s actual condition
| Accuracy Issue | Potential Consequence |
|---|---|
| False high reading | Insulin overdose, severe hypoglycemia |
| False low reading | Untreated hyperglycemia, DKA risk |
| Erratic fluctuations | User confusion, incorrect treatment decisions |
| Delayed reading updates | Missed glucose spikes or drops |
The Dexcom G7 is marketed as having a MARD (Mean Absolute Relative Difference) of 8.2%, meaning it should be accurate within about 8% of a lab reading. Plaintiffs allege that real-world accuracy falls far short of that claim.
Dexcom G7 Adhesive Problems Lawsuit
Dexcom G7 adhesive problems are a growing part of the lawsuit portfolio, with users reporting that the sensor patch peels off, loosens, or irritates the skin well before the 10-day wear period ends. When a sensor falls off, monitoring stops immediately.
This isn’t just an inconvenience. A detached sensor creates a monitoring gap. During that gap, the user’s glucose could spike or crash without any alarm going off.
Common adhesive complaints include:
- Premature detachment within 3 to 5 days of a 10-day sensor
- Skin irritation including redness, itching, and rash under the adhesive
- Allergic reactions to the adhesive material, sometimes requiring medical treatment
- Edge peeling that allows sweat or water to get under the sensor
Some users have reported developing contact dermatitis from the adhesive chemicals. In severe cases, this has left visible scarring on the skin at application sites.
| Adhesive Problem | Frequency Reported |
|---|---|
| Early detachment (before day 7) | Very common |
| Skin rash or irritation | Common |
| Allergic contact dermatitis | Less common but documented |
| Scarring at application site | Rare but reported |
Plaintiffs argue that Dexcom failed to adequately test the adhesive for long-term skin compatibility and that the company received early reports of adhesive issues but did not reformulate the product or add sufficient warnings.
Dexcom G7 FDA Complaints
Dexcom G7 FDA complaints are tracked through the MAUDE database, which is the FDA’s system for recording adverse events related to medical devices. As of early 2026, thousands of adverse event reports have been filed against the Dexcom G7.
The MAUDE database is publicly searchable. Anyone can look up reports filed by users, healthcare providers, and the manufacturer itself. These reports serve as critical evidence in product liability lawsuits.
Categories of FDA complaints for the G7 include:
- Device malfunction (sensor failure, signal loss, early termination)
- Injury (hypoglycemia, hyperglycemia, hospitalization caused by inaccurate readings)
- Death (a small number of reports involving fatal outcomes potentially linked to device failure)
The FDA has taken several actions related to Dexcom products:
- Class I recalls (the most serious type, indicating a reasonable chance of serious injury or death)
- Warning letters to Dexcom regarding manufacturing quality issues
- Post-market surveillance requirements for ongoing monitoring of device performance
| FDA Action Type | Significance |
|---|---|
| MAUDE adverse event reports | Documents user harm; evidence in lawsuits |
| Class I recall | Most serious; indicates risk of death or serious injury |
| Class II recall | Less serious; device may cause temporary harm |
| Warning letter | FDA formally notifies company of violations |
Quick Fact: The FDA classified at least one Dexcom CGM recall in recent years as Class I, the highest risk level. This classification strengthens plaintiffs’ arguments that Dexcom was aware of serious safety problems.
Key Takeaway: The FDA has received thousands of adverse event reports about the Dexcom G7, and past recalls classified at the highest risk level provide strong evidence for plaintiffs in the ongoing litigation.
Dexcom G7 Recall Lawsuit
The Dexcom G7 recall lawsuit refers to legal claims that are strengthened by or directly tied to FDA-initiated recalls of Dexcom CGM products. A recall signals that even the federal government recognized the device posed an unacceptable risk.
Dexcom has issued multiple recalls across its product line in recent years. While some recalls targeted the older G6 model, others involved components and software shared with the G7 system.
Recall-related claims argue that:
- Dexcom knew about the defect before the recall but kept selling the product
- The company delayed notifying the FDA and the public
- Users suffered injuries during the gap between when Dexcom knew about the problem and when the recall was announced
- The recall itself was insufficient, with many users never receiving proper notification
In product liability law, a recall is a double-edged sword for the manufacturer. It shows the company eventually did the right thing, but it simultaneously proves the product was defective.
| Recall Detail | What It Means for Your Case |
|---|---|
| Class I recall issued | Strongest possible evidence of danger |
| Delay between defect discovery and recall | Suggests corporate negligence |
| Inadequate user notification | Shows failure to warn consumers |
| Post-recall injuries | Proves the recall was too late or incomplete |
If you used a Dexcom G7 sensor that was later included in a recall batch, your lawsuit has a significant advantage. The recall itself does much of the legal heavy lifting in proving the device was defective.
How to File a Dexcom G7 Lawsuit
Filing a Dexcom G7 lawsuit in 2026 involves several clear steps, and most plaintiffs pay nothing upfront because attorneys handle these cases on a contingency fee basis. That means the lawyer only gets paid if you win or receive a settlement.
Here is the process, step by step:
Step 1: Gather your documentation.
Collect everything related to your Dexcom G7 use. This includes purchase receipts, prescription records, Dexcom app data, screenshots of error messages, medical records from any related ER visits or doctor appointments, and the defective sensor itself if you still have it.
Step 2: Contact a product liability attorney.
Look for a law firm that specifically handles medical device litigation. Many firms offer free case evaluations for Dexcom G7 claims.
Step 3: Complete a case intake form.
The attorney’s team will ask about your device, the problems you experienced, your medical history, and any injuries or financial losses.
Step 4: Sign a retainer agreement.
This formalizes the attorney-client relationship. Confirm the contingency fee percentage, which typically ranges from 33% to 40% of any settlement.
Step 5: Your attorney files the complaint.
The lawyer drafts and files the legal complaint in the appropriate court. You may not need to appear in court at all during the early stages.
| Filing Step | What You Need |
|---|---|
| Documentation | App screenshots, medical records, receipts |
| Attorney contact | Free case evaluation with product liability firm |
| Case intake | Answer questions about device use and injuries |
| Retainer | Sign contingency agreement (no upfront cost) |
| Filing | Attorney handles court filing |
Most people complete steps 1 through 4 within a week or two. The legal process itself takes much longer, but getting started is fast.
Dexcom G7 Lawsuit Timeline
The Dexcom G7 lawsuit timeline stretches across several years, with key milestones expected throughout 2026 and into 2027. Medical device lawsuits typically take 2 to 5 years from initial filing to settlement or verdict.
Here is where things stand and what to expect:
| Phase | Estimated Timing |
|---|---|
| Initial lawsuits filed | 2024 to 2025 |
| Additional claims and attorney investigations | Ongoing through 2026 |
| MDL petition and consolidation | Mid 2026 |
| Discovery (document exchange, depositions) | Q3 2026 to Q2 2027 |
| Bellwether trial selections | Late 2026 to early 2027 |
| First bellwether trials | 2027 |
| Settlement negotiations | 2027 to 2028 |
| Final settlement approval (if reached) | 2028 or later |
| Payout distribution | Following settlement approval |
Patience is required. Medical device litigation moves slowly because of the complexity of the evidence, the number of plaintiffs, and the financial stakes for the manufacturer.
That said, some individual cases may settle faster than the group litigation. If your injuries are severe and well-documented, your attorney may negotiate a separate early settlement with Dexcom.
The bellwether trial results will be the most important factor. If juries side with plaintiffs in the first few test cases, Dexcom will face enormous pressure to settle the remaining claims. If Dexcom wins those early trials, settlement values could drop.
Key Takeaway: The Dexcom G7 lawsuit timeline points to major developments in mid-to-late 2026, with potential settlement negotiations beginning in 2027 and payouts likely arriving in 2028 or later.
Dexcom G7 Settlement Tax Implications
Dexcom G7 settlement tax implications depend on what type of damages your payout covers. Physical injury compensation is generally tax-free under federal law, while other categories may be taxable.
The IRS follows a straightforward rule based on IRC Section 104(a)(2). If your settlement compensates you for physical injuries or physical sickness, you do not owe federal income tax on that money. This includes compensation for medical bills, physical pain, and suffering directly caused by the device.
However, other parts of a settlement may be taxed:
- Emotional distress damages (not connected to physical injury): Taxable
- Punitive damages: Taxable
- Lost wages or lost income: Taxable
- Interest on the settlement: Taxable
- Attorney fees (in some cases): May still be included in your taxable income
| Damage Type | Taxable? |
|---|---|
| Physical injury compensation | No |
| Medical expense reimbursement | No (if not previously deducted) |
| Emotional distress (with physical injury) | No |
| Emotional distress (without physical injury) | Yes |
| Punitive damages | Yes |
| Lost wages | Yes |
| Interest earned on settlement | Yes |
Your settlement agreement may itemize how the payout is allocated across these categories. That allocation matters enormously for your tax bill.
Quick Fact: If your Dexcom G7 settlement is $100,000 and $70,000 is allocated to physical injury, only the remaining $30,000 (emotional distress, lost wages, punitive) would potentially be taxable.
Dexcom G7 Lawsuit Settlement Funding
Dexcom G7 lawsuit settlement funding is a financial option that gives plaintiffs access to cash before their case settles. Also called pre-settlement funding or lawsuit loans, this money helps cover living expenses, medical bills, and other costs while the litigation plays out.
Here is how it works. A funding company reviews your case and, if approved, advances you money based on the expected settlement value. You repay the advance (plus fees) only when your case settles. If you lose your case, you typically owe nothing.
This is not a traditional loan. It’s non-recourse funding, meaning the funding company takes the risk. If there’s no payout, they absorb the loss.
Key details about settlement funding:
- Typical advance amounts: $1,000 to $100,000, depending on case value
- Interest rates: Usually 2% to 4% per month (compounding)
- Approval time: 24 to 48 hours in many cases
- Repayment: Only if you win or settle; nothing owed if you lose
| Funding Detail | Typical Terms |
|---|---|
| Minimum advance | $1,000 |
| Maximum advance | $100,000 |
| Interest rate | 2% to 4% monthly |
| Approval speed | 24 to 48 hours |
| Repayment required if case lost | No |
There is a significant downside. The interest rates are high compared to traditional lending. A $10,000 advance at 3% monthly compounding interest could grow to over $14,000 in just one year. If your case takes three years, the repayment amount could more than double.
Use settlement funding only if you genuinely need the money to get by while waiting. It should be a last resort, not a first option.
Key Takeaway: Settlement funding can provide financial relief while your Dexcom G7 case is pending, but the high interest rates mean you should only use it when necessary and understand the total cost before signing.
Frequently Asked Questions
Is there a class action lawsuit against Dexcom for the G7?
Yes, attorneys are pursuing class action claims alongside individual injury lawsuits against Dexcom for G7 problems.
Class action certification is still pending in 2026, but individual cases are actively being filed.
Both types of claims cover sensor failures, inaccurate readings, and adhesive defects.
How much money can I get from a Dexcom G7 lawsuit?
Estimated payouts range from $5,000 to $250,000 or more, depending on the severity of your injury.
Minor cases involving no hospitalization may settle for $5,000 to $25,000.
Serious injury cases involving hospitalization or lasting harm could reach six figures.
What problems with the Dexcom G7 qualify for a lawsuit?
Sensor failures, inaccurate glucose readings, adhesive detachment, and app connectivity issues all qualify.
Any malfunction that led to a medical event, ER visit, or financial loss strengthens your claim.
You do not need to have been hospitalized to file, though injuries increase your potential payout.
What is the deadline to file a Dexcom G7 lawsuit?
The deadline depends on your state’s statute of limitations for product liability claims, which ranges from 1 to 6 years in most states.
Some states start the clock from the date of injury, while others start from the date you discovered the device was defective.
Filing sooner is always better because evidence and memories are fresher.
Do I have to pay taxes on a Dexcom G7 settlement?
Settlement money for physical injuries is generally not taxable under federal law.
Portions of a settlement allocated to emotional distress, lost wages, or punitive damages may be taxable.
The way your settlement agreement allocates the payout directly affects your tax obligation.
What You Should Do Right Now
The Dexcom G7 lawsuit is gaining momentum in 2026, and the window to file remains open. If you experienced sensor failures, wrong readings, or any other G7 malfunction, your claim has value.
Gather your medical records, save your Dexcom app data, and reach out to a product liability attorney for a free case review. Acting now puts you in the strongest possible position before the litigation moves further along.
Your experience matters. The device was supposed to protect your health, not put it at risk.
